Health economics: Implications for novel antirheumatic therapies

Annals of the Rheumatic Diseases

Volumn 64, Issue SUPPL. 4, 2005, Pages

  Kavanaugh, A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ANTIBODY;

ATHEROSCLEROSIS; CONFERENCE PAPER; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG MARKETING; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; INFLAMMATORY DISEASE; OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST OF ILLNESS; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; TUMOR NECROSIS FACTORS;

EID: 27444446804     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.042440     Document Type: Conference Paper

References (61)

1. Pincus T, Kavanaugh A, Sokka T. Benefit/risk of therapies for rheumatoid arthritis: underestimation of the "side effects" or risks of RA leads to underestimation of the benefit/risk of therapies. Clin Exp Rheum 2004;22(suppl 35):S2-S11.
2. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
3. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
4. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
5. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443-50.
6. van de Putte LB, Rau R, Breedveld FC, Kalden JR, Malaise MG, van Riel PL, et al. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis 2003;62:1168-77.
7. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
8. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with inniximab and methotrexate. Arthritis Rheum 2004;50:1051-65.
9. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al; TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
10. Keystone E, Kavanaugh A, Sharp J, Tennenbaum H, Hua Y, Teoh L, et al. Radiographic, clinical, and functional outcomes with adalimumab (a human anti-TNF alpha monoclonal antibody) in the treatment of patients with active rheumatoid arthritis on concomitant methorexate theapy: a randomized, controlled, 52 week-trial. Arthritis Rheum 2004;50:1400-11.
11. Kavanaugh A, Cohen S, Cush J. The evolving use of TNF inhibitors in rheumatoid arthritis. J Rheumatol 2004;31:1881-4.
12. Wong J. Cost-effectiveness of anti-tumor necrosis factor agents. Clin Exp Rheumatol 2005;22(suppl. 35):S65-S70.
13. Lambert CM. Medical therapy for rheumatoid arthritis-value for money? Rheumatology 2001;40:961-4.
14. Hurst NP, Forbes J. Does economic evaluation have anything to offer the rheumatologist? Rheumatology 1999;38:2-5.
15. Ruff B. OMERACT: Economic evaluations and health policy. J Rheumatol 1999;26:2076-7.
16. Gabriel S, Tugwell P, O'Brien B, Yelin E, Drummond M, Ruff B, et al. Report of the OMERACT Task Force on Economic Evaluation. Outcome Measures in Rheumatology. J Rheumatol 1999;26:203-6.
17. Solomon D, Maetzel A. Pharmacoeconomics of prescribing for rheumatoid arthritis. Int J Adv Rheumatol 2004;2:91-6.
18. Weisman M, Gano A, Gabriel S, Hochberg MC, Kavanaugh A, Ofman JJ, et al; Evidence-Based Medicine Working Groups in Rheumatology. Reading and interpreting economic evaluations in rheumatoid arthritis: an assessment of selected instruments for critical appraisal. J Rheumatol 2003;30:1739-47.
19. Wolfe F, Michaud K, Pincus T. Do rheumatology cost-effectiveness analyses make sense? Rheumatol 2004;43:4-6.
20. Maetzel A. Cost-effectiveness analysis: out of touch with clinical reality? Arthritis Rheum (Arthritis Care Res) 2005;53:3-4.
21. Verstappen SMM, Boonen A, Verkleij H, Bijlsma JWJ, Buskens E, Jacobs JWG. Productivity costs among patients with rheumatoid arthritis: The influence of methods and sources to value loss of productivity. Ann Rheum Dis 2005 (published online-first 5 May 2005 doi 10.1136/ard.2004.033977).
22. Rat A-C, Boissier M-C. Rheumatoid arthritis: direct and indirect costs. Joint Bone Spine 2004;71:518-24.
23. Pisu M, James N, Sampsel S, Saag K. The cost of glucocorticoid-associated adverse events in rheumatoid arthritis. Rheumatology 2005 (in press).
24. Gabriel SE, Crowson CS, O'Fallon WM. Mortality in rheumatoid arthritis: have we made an impact in 4 decades? J Rheumatol 1999;26:2529-33.
25. Pincus T, Sokka T, Wolfe F. Premature mortality in patients with rheumatoid arthritis: evolving concepts. Arthritis Rheum 2001;44:1234-6.
26. Gabriel SE, Crowson CS, Kremers HM, et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003;48:54-8.
27. Pincus T, Brooks RH, Callahan LF. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann Intern Med 1994;120:26-34.
28. Jantti J, Aho K, Kaarela K, Kautiainen H. Work disability in an inception cohort of patients with seropositive rheumatoid arthritis: a 20 year study. Rheumatology 1999;38:1138-41.
29. Fex E, Larsson BM, Nived K, Eberhardt K. Effect of rheumatoid arthritis on work status and social and leisure time activities in patients followed 8 years from onset. J Rheumatol 1998;25:44-50.
30. Zink A, Braun J, Listing J, Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis-results from the German Rheumatological Database. J Rheumatol 2000;27:613-22.
31. Sokka T, Krishnan E, Hakkinen A, Hannonen P. Functional disability in rheumatoid arthritis patients compared with a community population in Finland. Arthritis Rheum 2003;48:59-63.
32. Wiles NJ, Scott DG, Barrett EM, et al. Benchmarking: the five year outcome of rheumatoid arthritis assessed using a pain score, the Health Assessment Questionnaire, and the Short Form-36 (SF-36) in a community and a clinic based sample. Ann Rheum Dis 2001;60:956-61.
33. Verstappen SMM, Bijlsma JWJ, Verkleij H, Buskens E, Blaauw AAM, ter Borg EJ, et al. Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys. Arthritis Rheum (Arthritis Care Res) 2004;51:488-97.
34. Birrell FN, Hassell AB, Jones PW, Dawes PT. How does the short form 36 health questionnaire (SF-36) in rheumatoid arthritis (RA) relate to RA outcome measures and SF-36 population values? A cross-sectional study. Clin Rheumatol 2000;19:195-9.
35. Wolfe F. The prognosis of rheumatoid arthritis: assessment of disease activity and disease severity in the clinic. Am J Med 1997;103:12S-18S.
36. Gabriel SE, Crowson CS, Campion ME, O'Fallon WM. Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls. J Rheumatol 1997;24:43-8.
37. Lajas C, Abasolo L, Bellajdel B, et al. Costs and predictors of costs in rheumatoid arthritis: a prevalence based study. Arthritis Rheum (Arthritis Care Res) 2003;49:64-70.
38. Dunlop D, Manheim L, Yelin E, Song J, Chang R. The costs of arthritis. Arthritis Rheum (Arthritis Care Res) 2003;49:101-13.
39. Maetzel A, Li LC, Tomlinson G, Bombardier C. The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Ann Rheum Dis 2004;63:395-401.
40. Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology 2000;39:28-33.
41. Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum 1999;42:1209-18.
42. Fries JF. Safety, cost and effectiveness issues with disease modifying anti-rheumatic drugs in rheumatoid arthritis. Ann Rheum Dis 1999;58(suppl I):I86-I89.
43. Kobelt G, Eberhardt K, Jonsson L, Jonsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999;42:347-56.
44. Kobelt G, Jonsson L, Lindgren P, Young A, Eberhardt K. Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheum 2002;46:2310-19.
45. Michaud K, Messer J, Choi H, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum 2003;48:2750-62.
46. Guillemin F. The value of utility: assumptions underlying preferences and quality adjusted life years. J Rheumatol 1999;26:1861-3.
47. Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med 2002;113:400-8.
48. Kobelt G, Jonsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology 2003;42:326-35.
49. Kobelt G, Eberhardt K, Geborek P. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis 2004;63:4-10.
50. Brennan A, Bansback N, Reynolds A, Conway P. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology 2004;43:62-72.
51. Kavanaugh A, Han C, Bala M. Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis. J Rheumatol 2004;31:849-55.
52. Yelin E, Trupin L, Katz P, Lubeck D, Rush S, Wanke L. Association between etanercept use and employment outcomes among patients with rheumatoid arthritis. Arthritis Rheum 2003;48:3046-54.
53. Bansback NJ, Brennan A, Sengupta N, Pang F. The cost effectiveness of adalimumab (HUMIRA) in UK patients with moderate to severe RA [abstract]. Ann Rheum Dis 2004;63(suppl 1):512-13.
54. Bansback NJ, Brennan A, Sengupta N. The cost effectiveness of adalimumab (HUMIRA) in patients with RA: a Finnish analysis [abstract]. Ann Rheum Dis 2004;63(suppl 1):513-14.
55. Choi HK, Seeger JD, Kuntz KM. A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis Rheum 2000;43:2316-27.
56. Kavanaugh A, Heudebert G, Cush J, Jain R. Cost evaluation of novel therapeutics in rheumatoid arthritis (CENTRA): a decision analysis model. Semin Arthritis Rheum 1996;25:297-307.
57. Hallert E, Husberg M, Jonsson D, Skogh T. Rheumatoid arthritis is already expensive during the first year of disease. Rheumatol 2004;43:1374-82.
58. Quinn M, Conaghan P, O'Connor P, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal. Arthritis Rheum 2005;52:27-35.
59. Kavanaugh A, Krueger G, Yan S, Bala M, Zhou B, Dooley L, et al. Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis. Arthritis Rheum 2004;50(suppl):S318.
60. Kobelt G, Sandlin-Sobocki P, Brophy S, Jonsson L, Calin A, Braun J. The burden of ankylosing spondylitis and the cost-effectiveness of treament with infliximab. Rheumatology 2004;43:1158-66.
61. Jonietz E. Generic biotech. Technol Rev 2004;107:54-8.